ANAB Relative Valuation
ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANAB is overvalued; if below, it's undervalued.
Historical Valuation
AnaptysBio Inc (ANAB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.87. The fair price of AnaptysBio Inc (ANAB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：44.70
Fair
-20.46
PE
1Y
3Y
5Y
Trailing
Forward
16.38
EV/EBITDA
AnaptysBio Inc. (ANAB) has a current EV/EBITDA of 16.38. The 5-year average EV/EBITDA is -1.99. The thresholds are as follows: Strongly Undervalued below -12.26, Undervalued between -12.26 and -7.12, Fairly Valued between 3.15 and -7.12, Overvalued between 3.15 and 8.29, and Strongly Overvalued above 8.29. The current Forward EV/EBITDA of 16.38 falls within the Strongly Overvalued range.
-27.62
EV/EBIT
AnaptysBio Inc. (ANAB) has a current EV/EBIT of -27.62. The 5-year average EV/EBIT is 0.39. The thresholds are as follows: Strongly Undervalued below -39.74, Undervalued between -39.74 and -19.68, Fairly Valued between 20.45 and -19.68, Overvalued between 20.45 and 40.52, and Strongly Overvalued above 40.52. The current Forward EV/EBIT of -27.62 falls within the Undervalued range.
8.31
PS
AnaptysBio Inc. (ANAB) has a current PS of 8.31. The 5-year average PS is 29.31. The thresholds are as follows: Strongly Undervalued below -20.58, Undervalued between -20.58 and 4.37, Fairly Valued between 54.25 and 4.37, Overvalued between 54.25 and 79.20, and Strongly Overvalued above 79.20. The current Forward PS of 8.31 falls within the Historic Trend Line -Fairly Valued range.
-22.77
P/OCF
AnaptysBio Inc. (ANAB) has a current P/OCF of -22.77. The 5-year average P/OCF is 18.79. The thresholds are as follows: Strongly Undervalued below -135.88, Undervalued between -135.88 and -58.54, Fairly Valued between 96.13 and -58.54, Overvalued between 96.13 and 173.46, and Strongly Overvalued above 173.46. The current Forward P/OCF of -22.77 falls within the Historic Trend Line -Fairly Valued range.
-18.72
P/FCF
AnaptysBio Inc. (ANAB) has a current P/FCF of -18.72. The 5-year average P/FCF is -5.98. The thresholds are as follows: Strongly Undervalued below -36.92, Undervalued between -36.92 and -21.45, Fairly Valued between 9.49 and -21.45, Overvalued between 9.49 and 24.96, and Strongly Overvalued above 24.96. The current Forward P/FCF of -18.72 falls within the Historic Trend Line -Fairly Valued range.
AnaptysBio Inc (ANAB) has a current Price-to-Book (P/B) ratio of -41.02. Compared to its 3-year average P/B ratio of 12.55 , the current P/B ratio is approximately -426.99% higher. Relative to its 5-year average P/B ratio of 8.32, the current P/B ratio is about -593.22% higher. AnaptysBio Inc (ANAB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.39%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.34% , the current FCF yield is about -100.00% lower.
-40.59
P/B
Median3y
12.55
Median5y
8.32
-11.99
FCF Yield
Median3y
-17.39
Median5y
-12.34
Competitors Valuation Multiple
The average P/S ratio for ANAB's competitors is 0.00, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ANAB increased by 227.04% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.18 to -15.06.
The secondary factor is the Revenue Growth, contributed 154.26%to the performance.
Overall, the performance of ANAB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is AnaptysBio Inc (ANAB) currently overvalued or undervalued?
What is AnaptysBio Inc (ANAB) fair value?
How does ANAB's valuation metrics compare to the industry average?
What is the current P/B ratio for AnaptysBio Inc (ANAB) as of Dec 05 2025?
What is the current FCF Yield for AnaptysBio Inc (ANAB) as of Dec 05 2025?
What is the current Forward P/E ratio for AnaptysBio Inc (ANAB) as of Dec 05 2025?